Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation

Farah Abuazzam; Casey Dubrawka; Tarek Abdulhadi; Gwendolyn Amurao; Louai Alrata; Dema Yaseen Alsabbagh; Omar Alomar; Tarek Alhamad

doi:10.3390/jcm12154916

Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation

Farah Abuazzam, Casey Dubrawka, Tarek Abdulhadi, Gwendolyn Amurao, Louai Alrata, Dema Yaseen Alsabbagh, Omar Alomar, Tarek Alhamad

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.

Original language	English
Article number	4916
Journal	Journal of Clinical Medicine
Volume	12
Issue number	15
DOIs	https://doi.org/10.3390/jcm12154916
State	Published - Aug 2023

Keywords

T-cell mediated rejection
allograft rejection
antibody-mediated rejection
kidney graft function
kidney transplant
mix rejection
transplant immunology

Access to Document

10.3390/jcm12154916

Cite this

@article{b9a473dd067143bb85e071607dabdef2,

title = "Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation",

abstract = "Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.",

keywords = "T-cell mediated rejection, allograft rejection, antibody-mediated rejection, kidney graft function, kidney transplant, mix rejection, transplant immunology",

author = "Farah Abuazzam and Casey Dubrawka and Tarek Abdulhadi and Gwendolyn Amurao and Louai Alrata and {Yaseen Alsabbagh}, Dema and Omar Alomar and Tarek Alhamad",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = aug,

doi = "10.3390/jcm12154916",

language = "English",

volume = "12",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

number = "15",

}

TY - JOUR

T1 - Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation

AU - Abuazzam, Farah

AU - Dubrawka, Casey

AU - Abdulhadi, Tarek

AU - Amurao, Gwendolyn

AU - Alrata, Louai

AU - Yaseen Alsabbagh, Dema

AU - Alomar, Omar

AU - Alhamad, Tarek

PY - 2023/8

Y1 - 2023/8

N2 - Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.

AB - Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.

KW - T-cell mediated rejection

KW - allograft rejection

KW - antibody-mediated rejection

KW - kidney graft function

KW - kidney transplant

KW - mix rejection

KW - transplant immunology

UR - http://www.scopus.com/inward/record.url?scp=85167661482&partnerID=8YFLogxK

U2 - 10.3390/jcm12154916

DO - 10.3390/jcm12154916

M3 - Review article

C2 - 37568318

AN - SCOPUS:85167661482

SN - 2077-0383

VL - 12

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 15

M1 - 4916

ER -

Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this